Widely used kidney cancer drugs can’t stop recurrence
Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer – sorafenib and sunitinib – are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania. Naomi B. Haas, MD, an associate professor in [...]